ARTICLE | Market Access
By decreasing Medicare’s contribution to branded Part D drugs, the act can make generic drugs cheaper for plans — even after manufacturer rebates
By Richard Guy, Biopharma Analyst
April 25, 2024 1:04 AM UTC


Changes in the Medicare Part D benefit structure will reduce, but not eliminate, health plan incentives to prefer high-priced brand drugs over generic competitors. Unlike the IRA price negotiations, which will affect 10 drugs in the first year, the IRA benefit restructuring affects all Part D sales.
Medicare Part D, which helps Medicare patients pay for drugs that they administer to themselves such as orals and certain injectables, has long been criticized for favoring high-cost drugs in part by allowing health plans to keep the lion’s share of the manufacturer rebates that accompany those drugs, and basing the amount of money it contributes on a drug’s price before any rebates have been applied. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651828/the-ira-s-boost-to-generics